Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00211276
Status:
COMPLETED
Last Update Posted:
2012-03-14
First Post:
2005-09-13
Brief Title:
A Study of ONTAK in Patients With Relapsed or Refractory B-Cell Non Hodgkins Lymphoma
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A Phase II Multicenter Study of ONTAK in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2011-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to find out if the study drug ONTAK denileukin diftitox can shrink or slow the growth of B-cell non-Hodgkins lymphoma NHL in patients whose disease has not responded to prior treatments or has relapsed after an initial response to prior treatments The safety of treatment with ONTAK will also be studied The hypothesis is that patients with relapsed or refractory B-cell NHL and mild to moderate myelosuppression treated with ONTAK at a new dosing regimen will respond sufficiently to warrant further study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None